A review of polymorphisms in the human gene for inducible nitric oxide synthase (NOS2) in patients with malaria

Sepsis

Volumn 4, Issue 3, 2001, Pages 217-231

  Levesque, Marc C ^a   Hobbs, Maurine R ^b   Anstey, Nicholas M ^c   Chancellor, Jennifer A ^a   Misukonis, Mary A M ^a   Granger, Donald L ^b   Weinberg, J Brice ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^c MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE; MICROSATELLITE DNA; NITRIC OXIDE SYNTHASE; UNCLASSIFIED DRUG;

BRAIN MALARIA; CELL HETEROGENEITY; DISEASE COURSE; DISEASE SEVERITY; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC EPIDEMIOLOGY; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; POPULATION RESEARCH; PROMOTER REGION; REVIEW; TRANSCRIPTION REGULATION;

EID: 0035652811     PISSN: 13850229     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012913023602     Document Type: Review

References (98)

1. Severe and complicated malaria
2. The immunogenetics of human infectious diseases
3. Polymorphism in promoter region of inducible nitric oxide synthase gene and protection against malaria
4. Inducible nitric oxide synthase polymorphism and fatal cerebral malaria
5. Nitric oxide synthase type 2 promoter polymorphisms, nitric oxide production and disease severity in Tanzania children with malaria
6. Perspectives series: Host/pathogen interactions. Mechanisms of nitric oxide-related antimicrobial activity
7. Inducible nitric oxide synthase: What difference does it make?
8. Nitric oxide and parasitic disease
9. Nitric oxide in malaria
10. Proposed link between cytokines, nitric oxide, and human cerebral malaria
11. The L-arginine-nitric oxide pathway
12. Nitric oxide: A novel mediator of inflammation
13. Nitric oxide production and nitric oxide synthase type 2 expression by human mononuclear phagocytes: A review
14. Nitric oxide: A physiologic messenger molecule
15. Nitric oxide in sepsis
16. Pyridoxalated hemoglobin polyoxyethylene: A nitric oxide scavenger with antioxidant activity for the treatment of nitric oxide-induced shock
17. The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: Increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-L-arginine
18. Nitric-oxide-induced apoptosis in human leukemic lines requires mitochondrial lipid degradation and cytochrome C release
19. The chemistry of nitric oxide and redox-related species
20. Induction of nitric oxide synthase protects against malaria in mice exposed to irradiated Plasmodium berghei infected mosquitoes: Involvement of interferon gamma and CD8+ T cells
21. Killing of Plasmodium falciparum in vitro by nitric oxide derivatives
22. Antimalarial activity of nitric oxide: Cytostasis and cytotoxicity towards Plasmodium falciparum
23. Inducible nitric oxide synthase in the liver: Regulation and function
24. Splenic B lymphocyte programmed cell death is prevented by nitric oxide release through mechanisms involving sustained Bcl-2 levels
25. Suppression of apoptosis by nitric oxide via inhibition of interleukin-1beta-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases
26. Nitric oxide reversibly inhibits seven members of the caspase family via S-nitrosylation
27. Inhibition of caspase-3 by S-nitrosation and oxidation caused by nitric oxide
28. Fas-induced caspase denitrosylation
29. Nitric oxide synthase inhibitors have opposite effects on acute inflammation depending on their route of administration
30. Selective inhibition of inducible nitric oxide synthase exacerbates erosive joint disease
31. Molecular cloning, structure, and chromosomal localization of the human inducible nitric oxide synthase gene
32. Transcriptional regulation of human inducible nitric oxide synthase (NOS2) gene by cytokines: Initial analysis of the human NOS2 promoter
33. Transcriptional regulation of human inducible nitric oxide synthase gene in an intestinal epithelial cell line
34. Analysis of expression and promoter function of the human inducible nitric oxide synthase gene in DLD-1 cells and monkey hepatocytes
35. Multiple NF-kappaB enhancer elements regulate cytokine induction of the human inducible nitric oxide synthase gene
36. Cytokine-mediated transcriptional induction of the human inducible nitric oxide synthase gene requires both activator protein 1 and nuclear factor kappaB-binding sites
37. Cytokine induction of NO synthase II in human DLD-1 cells: Roles of the JAKSTAT, AP-1 and NF-kappaB-signaling pathways
38. Molecular regulation of inducible nitric oxide synthase
39. Alternative splicing of human inducible nitric-oxide synthase mRNA. Tissue-specific regulation and induction by cytokines
40. Complex contribution of the 3′-untranslated region to the expressional regulation of the human inducible nitric-oxide synthase gene. Involvement of the RNA-binding protein HuR
41. Cytokine-induced changes in chromatin structure and in vivo footprints in the inducible NOS promoter
42. Human mononuclear phagocyte inducible nitric oxide synthase (iNOS): Analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages
43. Interferon (IFN)-alpha activation of human blood mononuclear cells in vitro and in vivo for nitric oxide synthase (NOS) type 2 mRNA and protein expression: Possible relationship of induced NOS2 to the anti-hepatitis C effects of IFN-alpha in vivo
44. Reduction of NOS2 overexpression in rheumatoid arthritis patients treated with anti-tumor necrosis factor alpha monoclonal antibody (cA2)
45. A central role for IL-1 beta in the in vitro and in vivo regulation of hepatic inducible nitric oxide synthase. IL-1 beta induces hepatic nitric oxide synthesis
46. Differential expression of iNOS and cNOS mRNA in human vascular smooth muscle cells and endothelial cells under normal and inflammatory conditions
47. Regulation of nitric oxide synthesis by proinflammatory cytokines in human umbilical vein endothelial cells. Elevations in tetrahydrobiopterin levels enhance endothelial nitric oxide synthase specific activity
48. Inducible nitric oxide and prostacyclin productions are differently controlled by extracellular matrix and cell density in human vascular endothelial cells
49. Glycosylphosphatidylinositol toxin of Plasmodium induces nitric oxide synthase expression in macrophages and vascular endothelial cells by a protein tyrosine kinase-dependent and protein kinase C-dependent signaling pathway
50. Human inducible nitric oxide synthase gene is transcriptionally regulated by nuclear factor-kappaB dependent mechanism
51. Transcriptional regulation of the human iNOS gene in vascular-smooth-muscle cells and macrophages: Evidence for tissue specificity
52. Synergistic regulation of inducible nitric oxide synthase gene by CCAAT/enhancer-binding protein beta and nuclear factor-kappaB in hepatocytes
53. Human- and mouse-inducible nitric oxide synthase promoters require activation of phosphatidylcholine-specific phospholipase C and NF-kappa B
54. Analysis of the cytokine- stimulated human inducible nitric oxide synthase (iNOS) gene: Characterization of differences between human and mouse iNOS promoters
55. Nitric oxide in cerebral malaria
56. Patients with Plasmodium falciparum malaria and Plasmodium vivax malaria show increased nitrite and nitrate plasma levels
57. Enhanced production of reactive nitrogen intermediates in human and murine malaria
58. Association between serum levels of reactive nitrogen intermediates and coma in children with cerebral malaria in Papua New Guinea
59. Serum creatinine levels and reactive nitrogen intermediates in children with cerebral malaria in Papua New Guinea
60. High plasma levels of nitrogen oxides are associated with severe disease and correlate with rapid parasitological and clinical cure in Plasmodium falciparum malaria
61. Modulatory potential of iron chelation therapy on nitric oxide formation in cerebral malaria
62. The ratio of reactive nitrogen intermediates to tumour necrosis factor and clinical outcome of falciparum malaria disease
63. Reactive nitrogen intermediates and outcome in severe adult malaria
64. Levels of circulating nitrate/nitrite and gamma interferon not increased in uncomplicated malaria
65. Lipid peroxides, nitric oxide and essential fatty acids in patients with Plasmodium falciparum malaria
66. Nitric oxide in Tanzanian children with malaria: Inverse relationship between malaria severity and nitric oxide production/nitric oxide synthase type 2 expression
67. High levels of inducible nitric oxide synthase mRNA are associated with increased monocyte counts in blood and have a beneficial role in Plasmodium falciparum malaria
68. Blood mononuclear cell nitric oxide production and plasma cytokine levels in healthy gabonese children with prior mild or severe malaria
69. Lambarene mutation, increased nitric oxide production and protection against malaria
70. Plasma nitrogen oxides and blood lactate concentrations in Ghanaian children with malaria
71. Nitric oxides in plasma, urine, and cerebrospinal fluid in patients with severe falciparum malaria
72. Cerebrospinal fluid levels of biopterin, nitric oxide metabolites, and immune activation markers and the clinical course of human cerebral malaria
73. Inducible nitric oxide synthase expression is increased in the brain in fatal cerebral malaria
74. Salicylates, nitric oxide, malaria, and Reye's syndrome
75. Tumor necrosis factor and disease severity in children with falciparum malaria
76. TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria
77. Variation in the tnf-alpha promoter region associated with susceptibility to cerebral malaria
78. Methods of analyzing nitric oxide production in the immune response
79. Nitric oxide, malaria, and anemia: Inverse relationship between nitric oxide production and hemoglobin concentration in asymptomatic, malaria-exposed children
80. Compartmentalised inducible nitric-oxide synthase activity in septic shock
81. The biological basis of malarial disease
82. Low interleukin-12 activity in severe Plasmodium falciparum malaria
83. IL-10 inhibits parasite killing and nitrogen oxide production by IFNgamma-activated macrophages
84. Reduced interleukin-12 and transforming growth factor-β1 in severe childhood malaria: Relationship of cytokine balance with disease severity
85. Effects of Plasmodium vinckei hemozoin on the production of oxygen radicals and nitrogen oxides in murine macrophages
86. The heme moiety of malaria pigment (beta-hematin) mediates the inhibition of nitric oxide and tumor necrosis factor-alpha production by lipopolysaccharide-stimulated macrophages
87. Inverse relationship of plasma prostaglandin E-2 and blood mononuclear cell cyclooxygenase-2 with disease severity in children with Plasmodium falciparum malaria
88. Nitric oxide synthase/COX cross-talk: Nitric oxide activates COX-1 but inhibits COX-2-derived prostaglandin production
89. Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus
90. Correlation of serum measures of nitric oxide production with lupus disease activity
91. Inherited variability of tumor necrosis factor production and susceptibility to infectious disease
92. Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: Relevance to disease
93. Linkage disequilibrium of a type 1 diabetes susceptibility locus with a regulatory IL12B allele
94. Inducible nitric oxide synthase (NOS2) gene polymorphism and parasitic diseases
95. Evolution of a homopurine-homopyrimidine pentanucleotide repeat sequence upstream of the human inducible nitric oxide synthase gene
96. Survey of the allelic frequency of a NOS2A promoter microsatellite in human populations: Assessment of the NOS2A gene and predisposition to infectious disease
97. Genotyping and functional analysis of a polymorphic (CCTTT)(n) repeat of NOS2A in diabetic retinopathy
98. An unprocessed pseudogene of inducible nitric oxide synthase gene in human